<DOC>
	<DOCNO>NCT02983695</DOCNO>
	<brief_summary>This Phase 1 trial determine tolerability optimal dose CBD rich cannabis extract adjunct treatment child severe drug resistant epilepsy due Dravet Syndrome . This open label intervention . Study duration 20 week primary analysis continue follow-up 64 week complete .</brief_summary>
	<brief_title>Cannabinoid Therapy Pediatric Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Drug resistant epilepsy due Dravet syndrome Must clinically apparent seizure Must able tolerate administration medication orally enterally via gastrostomy tube Was never Cannabinoid therapy treat Cannabinoid product least last 60 day ( confirm negative urine test Tetrahydrocannabidiol ( THC ) , treat CBD ) . Comorbid liver renal disease Without clinicallyapparent seizure Currently take Cannabinoid product .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>